Genomic Testing and Resulting Medical Decisions
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cancer Head &Neck
- Cancer Cervix
- Cancer, Uterus
- Hematologic Neoplasms
- Cancer Colorectal
- Cancer Liver
- Cancer of Esophagus
- Cancer of Skin
- Cancer, Lung
- Cancer of Stomach
- Cancer of Unknown Origin
- Cancer, Kidney
- Cancer Refractory
- Cancer, Bladder
- Cancer Breast
- Design
- Observational Model: OtherTime Perspective: Other
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
In the situation of enormous possible beneficial options for patients, health care systems, researchers and companies and the simultaneously present high number of uncertainties, the establishment of an independent registry for patients undergoing any type of comprehensive genomic profiling offers m...
In the situation of enormous possible beneficial options for patients, health care systems, researchers and companies and the simultaneously present high number of uncertainties, the establishment of an independent registry for patients undergoing any type of comprehensive genomic profiling offers many advantages. In particular, an overview of the speed of development, the "market penetration", the use of the technology in specific indications (tumor types, stages and in specific situations of unresponsiveness to certain drugs), the frequency by which treatment decisions will definitely follow the result of comprehensive genomic profiling and the reasons for this, the treatment outcome of such patients, the platform technologies applied (in-house (which types), vs. commercial) and the development of these parameters over time and in relation to the development of novel drugs will be analyzed. The registry proposes to cover the time period from the years 2016 to 2019, which will allow for assessment of both the current and emerging landscape of genomic/molecular testing practice in Austria and effect of molecular profiling on patient care and outcome.
Tracking Information
- NCT #
- NCT03301493
- Collaborators
- Roche Pharma AG
- Investigators
- Principal Investigator: Richard Greil, MD IIIrd Medical Department, Private Medical University Hospital Salzburg